Samlyn Capital’s Immunocore IMCR Stock Holding History

Samlyn Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-380,811	Closed	-$11.4M	–	101
2022 Q1	$11.4M	Buy	+380,811	New	+$9.61M	0.16%	86

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Samlyn Capital's IMCR Position: Q2 2022 in Review

Samlyn Capital sold out of Immunocore (IMCR) in Q2 2022, closing a stake of 380,811 shares — an estimated $11.4M sold.

Samlyn Capital first reported a position in IMCR in Q1 2022 and held it in 1 quarter. The position peaked at $11.4M in Q1 2022. 66 funds tracked by Wall St. Rank hold IMCR as of Q2 2022.

Samlyn Capital reported no remaining Immunocore position as of Q2 2022 after selling out during the quarter.
Samlyn Capital sold 380,811 Immunocore shares in Q2 2022, an estimated $11.4M.
Samlyn Capital first reported a position in Immunocore in Q1 2022 and held it in 1 quarter.
Samlyn Capital's Immunocore position peaked at $11.4M in Q1 2022.
66 funds tracked by Wall St. Rank held Immunocore as of Q2 2022.

Based on Samlyn Capital's 13F filing for Q2 2022, filed 15 Aug 2022.